Search
Now showing items 1-1 of 1
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
(2023)
BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges ...